Fifth Third Bancorp Has $43.69 Million Holdings in Gilead Sciences, Inc. $GILD

Fifth Third Bancorp boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 393,565 shares of the biopharmaceutical company’s stock after purchasing an additional 14,642 shares during the quarter. Fifth Third Bancorp’s holdings in Gilead Sciences were worth $43,686,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Csenge Advisory Group lifted its holdings in shares of Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 16,288 shares in the last quarter. Cookson Peirce & Co. Inc. raised its stake in Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after purchasing an additional 7,168 shares in the last quarter. Railway Pension Investments Ltd boosted its holdings in Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the period. TriaGen Wealth Management LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $1,274,000. Finally, iA Global Asset Management Inc. increased its holdings in shares of Gilead Sciences by 11.6% during the third quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after purchasing an additional 23,046 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This trade represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 288,891 shares of company stock worth $40,303,946. Company insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GILD. BMO Capital Markets boosted their price target on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. Citigroup raised their target price on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Sanford C. Bernstein reissued an “outperform” rating and set a $160.00 price target on shares of Gilead Sciences in a report on Wednesday, February 11th. Finally, Truist Financial upped their price objective on Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $152.50.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $154.98 on Tuesday. The stock has a 50-day moving average price of $130.94 and a two-hundred day moving average price of $122.68. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a market capitalization of $192.28 billion, a PE ratio of 22.89, a P/E/G ratio of 2.06 and a beta of 0.36. The company has a current ratio of 1.68, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.68%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.